Trial Profile
An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Imlifidase (Primary)
- Indications Guillain-Barre syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Hansa Biopharma AB
- 06 Mar 2024 Status changed from active, no longer recruiting to completed.
- 07 Dec 2023 Positive high-level results presented in the Hansa Biopharma AB Media Release.
- 26 Oct 2023 According to a Hansa Biopharma AB media release, first data readout from this study will be in Q4 2023.